Global Live Attenuated Influenza Vaccine (LAIV) 麻豆原创 Growth 2025-2031

Publication ID:

LPI03258888

Publication Date:

March 5, 2025

Pages:

115

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Live Attenuated Influenza Vaccine (LAIV) market size is predicted to grow from US$ 8858 million in 2025 to US$ 12950 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.
A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.
Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.
Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine"s effectiveness is crucial in maintaining public confidence and its role in influenza prevention.
Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine"s effectiveness.
Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.
The 鈥淟ive Attenuated Influenza Vaccine (LAIV) Industry Forecast鈥� looks at past sales and reviews total world Live Attenuated Influenza Vaccine (LAIV) sales in 2024, providing a comprehensive analysis by region and market sector of projected Live Attenuated Influenza Vaccine (LAIV) sales for 2025 through 2031. With Live Attenuated Influenza Vaccine (LAIV) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Influenza Vaccine (LAIV) industry.
This Insight Report provides a comprehensive analysis of the global Live Attenuated Influenza Vaccine (LAIV) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Influenza Vaccine (LAIV) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Live Attenuated Influenza Vaccine (LAIV) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Influenza Vaccine (LAIV) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Influenza Vaccine (LAIV).
This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Influenza Vaccine (LAIV) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Segmentation by Application:
Hospital
Clinic
Public Health Agency
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Live Attenuated Influenza Vaccine (LAIV) market?
What factors are driving Live Attenuated Influenza Vaccine (LAIV) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Live Attenuated Influenza Vaccine (LAIV) market opportunities vary by end market size?
How does Live Attenuated Influenza Vaccine (LAIV) break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Country/Region, 2020, 2024 & 2031
2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
2.2.1 Trivalent Flu Vaccine
2.2.2 Quadrivalent Flu Vaccine
2.3 Live Attenuated Influenza Vaccine (LAIV) Sales by Type
2.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Type (2020-2025)
2.4 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Public Health Agency
2.4.4 Other
2.5 Live Attenuated Influenza Vaccine (LAIV) Sales by Application
2.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Breakdown Data by Company
3.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Company (2020-2025)
3.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Company (2020-2025)
3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Company (2020-2025)
3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Company
3.4 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Location Distribution
3.4.2 Players Live Attenuated Influenza Vaccine (LAIV) Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region
4.1 World Historic Live Attenuated Influenza Vaccine (LAIV) 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Live Attenuated Influenza Vaccine (LAIV) 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.4 APAC Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.5 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Growth
4.6 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Growth
5 Americas
5.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country
5.1.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025)
5.1.2 Americas Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025)
5.2 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025)
5.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region
6.1.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025)
6.1.2 APAC Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2020-2025)
6.2 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025)
6.3 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Live Attenuated Influenza Vaccine (LAIV) by Country
7.1.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025)
7.1.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025)
7.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025)
7.3 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) by Country
8.1.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2020-2025)
8.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2020-2025)
8.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV)
10.3 Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
10.4 Industry Chain Structure of Live Attenuated Influenza Vaccine (LAIV)
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live Attenuated Influenza Vaccine (LAIV) Distributors
11.3 Live Attenuated Influenza Vaccine (LAIV) Customer
12 World Forecast Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region
12.1 Global Live Attenuated Influenza Vaccine (LAIV) 麻豆原创 Size Forecast by Region
12.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Region (2026-2031)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Type (2026-2031)
12.7 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 CSL
13.3.1 CSL Company Information
13.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 CSL Main Business Overview
13.3.5 CSL Latest Developments
13.4 Abbott
13.4.1 Abbott Company Information
13.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Abbott Main Business Overview
13.4.5 Abbott Latest Developments
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Information
13.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 GlaxoSmithKline Main Business Overview
13.5.5 GlaxoSmithKline Latest Developments
13.6 Serum Institute
13.6.1 Serum Institute Company Information
13.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Serum Institute Main Business Overview
13.6.5 Serum Institute Latest Developments
13.7 Fluenz Tetra
13.7.1 Fluenz Tetra Company Information
13.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Fluenz Tetra Main Business Overview
13.7.5 Fluenz Tetra Latest Developments
13.8 Cytiva
13.8.1 Cytiva Company Information
13.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Cytiva Main Business Overview
13.8.5 Cytiva Latest Developments
13.9 BioDiem
13.9.1 BioDiem Company Information
13.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 BioDiem Main Business Overview
13.9.5 BioDiem Latest Developments
13.10 FluMist
13.10.1 FluMist Company Information
13.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 FluMist Main Business Overview
13.10.5 FluMist Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
13.12 ChangChun High & New Technology
13.12.1 ChangChun High & New Technology Company Information
13.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 ChangChun High & New Technology Main Business Overview
13.12.5 ChangChun High & New Technology Latest Developments
13.13 BCHT Biotechnology
13.13.1 BCHT Biotechnology Company Information
13.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Portfolios and Specifications
13.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 BCHT Biotechnology Main Business Overview
13.13.5 BCHT Biotechnology Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.